Skip to main content
Fig. 5 | Experimental Hematology & Oncology

Fig. 5

From: A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Fig. 5

The robust expansion of CAR-T cells and antileukemic activity of sequential CD22/CD19 CAR-T therapy. a Response and long term follow-up of each patient who received CD22/CD19 CAR-T sequential therapy. b Percentage of circulating CAR-T (Fab positive T) cells in total T cells analyzed by flow cytometry. c, d Copy numbers of CD22 CAR C and CD19 CAR D which integrated in genomic DNA per μg PBMC genomic DNA in each patient at different time points

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us